|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chudecka-Glaz AM: ROMA, an algorithm for
ovarian cancer. Clin Chim Acta. 440:143–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bai Y, Li LD, Li J and Lu X: Targeting of
topoisomerases for prognosis and drug resistance in ovarian cancer.
J Ovarian Res. 9:352016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Karst AM and Drapkin R: Ovarian cancer
pathogenesis: A model in evolution. J Oncol. 2010:9323712010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ozols RF: Role of carboplatin in ovarian
cancer. Current results and thoughts for the future. Acta Obstet
Gynecol Scand Suppl. 155:75–77. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pinato DJ, Graham J, Gabra H and Sharma R:
Evolving concepts in the management of drug resistant ovarian
cancer: Dose dense chemotherapy and the reversal of clinical
platinum resistance. Cancer Treat Rev. 39:153–160. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pénzváltó Z, Lánczky A, Lénárt J,
Meggyesházi N, Krenács T, Szoboszlai N, Denkert C, Pete I and
Győrffy B: MEK1 is associated with carboplatin resistance and is a
prognostic biomarker in epithelial ovarian cancer. BMC Cancer.
14:8372014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barghout SH, Zepeda N, Vincent K, Azad AK,
Xu Z, Yang C, Steed H, Postovit LM and Fu Y: RUNX3 contributes to
carboplatin resistance in epithelial ovarian cancer cells. Gynecol
Oncol. 138:647–655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peters D, Freund J and Ochs RL:
Genome-wide transcriptional analysis of carboplatin response in
chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer
Ther. 4:1605–1616. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Konstantinopoulos PA, Fountzilas E, Pillay
K, Zerbini LF, Libermann TA, Cannistra SA and Spentzos D:
Carboplatin-induced gene expression changes in vitro are prognostic
of survival in epithelial ovarian cancer. BMC Med Genomics.
1:592008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: Affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Irizarry RA, Hobbs B, Collin F,
Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Diboun I, Wernisch L, Orengo CA and
Koltzenburg M: Microarray analysis after RNA amplification can
detect pronounced differences in gene expression using limma. BMC
Genomics. 7:2522006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sherman BT, da Huang W, Tan Q, Guo Y, Bour
S, Liu D, Stephens R, Baseler MW, Lane HC and Lempicki RA: DAVID
Knowledgebase: A gene-centered database integrating heterogeneous
gene annotation resources to facilitate high-throughput gene
functional analysis. BMC Bioinformatics. 8:4262007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:(Database Issue). D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li B, Gao Y, Rankin GO, Rojanasakul Y,
Cutler SJ, Tu Y and Chen YC: Chaetoglobosin K induces apoptosis and
G2 cell cycle arrest through p53-dependent pathway in
cisplatin-resistant ovarian cancer cells. Cancer Lett. 356:418–433.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tu Y, Kim E, Gao Y, Rankin GO, Li B and
Chen YC: Theaflavin-3, 3′-digallate induces apoptosis and G2 cell
cycle arrest through the Akt/MDM2/p53 pathway in
cisplatin-resistant ovarian cancer A2780/CP70 cells. Int J Oncol.
48:2657–2665. 2016.PubMed/NCBI
|
|
19
|
Meng E, Mitra A, Tripathi K, Finan MA,
Scalici J, McClellan S, da Madeira Silva L, Reed E, Shevde LA,
Palle K and Rocconi RP: ALDH1A1 maintains ovarian cancer stem
cell-like properties by altered regulation of cell cycle checkpoint
and DNA repair network signaling. PLoS One. 9:e1071422014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Raman M, Chen W and Cobb MH: Differential
regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Davis RJ: MAPKs: New JNK expands the
group. Trends Biochem Sci. 19:470–473. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Klotz R, Zeimet AG, Reimer D,
Müller-Holzner E, Chamson M and Marth C: Activated p38-MAPK and
gemcitabine sensitivity in recurrent ovarian cancer. Anticancer
Res. 28:2975–2980. 2008.PubMed/NCBI
|
|
23
|
Losa J Hernández, Cobo C Parada, Viniegra
J Guinea, Lobo VJ Sánchez-Arevalo, Cajal S Ramón y and
Sánchez-Prieto R: Role of the p38 MAPK pathway in cisplatin-based
therapy. Oncogene. 22:3998–4006. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kong LR, Chua KN, Sim WJ, Ng HC, Bi C, Ho
J, Nga ME, Pang YH, Ong WR, Soo RA, et al: MEK Inhibition overcomes
cisplatin resistance conferred by SOS/MAPK pathway activation in
squamous cell carcinoma. Mol Cancer Ther. 14:1750–1760. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Iwamori M, Tanaka K, Kubushiro K, Lin B,
Kiguchi K, Ishiwata I, Tsukazaki K and Nozawa S: Alterations in the
glycolipid composition and cellular properties of ovarian
carcinoma-derived RMG-1 cells on transfection of the
alpha1,2-fucosyltransferase gene. Cancer Sci. 96:26–30. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yan L, Lin B, Gao L, Gao S, Liu C, Wang C,
Wang Y, Zhang S and Iwamori M: Lewis (y) antigen overexpression
increases the expression of MMP-2 and MMP-9 and invasion of human
ovarian cancer cells. Int J Mol Sci. 11:4441–4452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu D, Liu J, Wang C, Lin B, Liu Q, Hao Y,
Zhang S and Iwamori M: The stimulation of IGF-1R expression by
Lewis(y) antigen provides a powerful development mechanism of
epithelial ovarian carcinoma. Int J Mol Sci. 12:6781–6795. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao N, Liu J, Liu D, Hao Y, Yan L, Ma Y,
Zhuang H, Hu Z, Gao J, Yang Z, et al: c-Jun transcriptionally
regulates alpha 1, 2-fucosyltransferase 1 (FUT1) in ovarian cancer.
Biochimie. 107:Pt B. 286–292. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Echevarría-Vargas IM, Valiyeva F and
Vivas-Mejía PE: Upregulation of miR-21 in cisplatin resistant
ovarian cancer via JNK-1/c-Jun pathway. PLoS One. 9:e970942014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang CC, Hung CM, Yang YR, Lee MJ and Hsu
YC: Sulforaphane induced cell cycle arrest in the G2/M phase via
the blockade of cyclin B1/CDC2 in human ovarian cancer cells. J
Ovarian Res. 6:412013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zheng H, Hu W, Deavers MT, Shen DY, Fu S,
Li YF and Kavanagh JJ: Nuclear cyclin B1 is overexpressed in
low-malignant-potential ovarian tumors but not in epithelial
ovarian cancer. Am J Obstet Gynecol. 201:367.e1–6. 2009. View Article : Google Scholar
|
